Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrea Worschech

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Trends in Immunology|May 7, 2008
The immunologic constant of rejectionEna Wang, Andrea Worschech, Francesco M Marincola
Advances in Experimental Medicine and Biology|August 28, 2010
Analysis of vaccine-induced T cells in humans with cancerStefanie L Slezak, Andrea Worschech, Ena Wang, et al.
Cancer Immunology, Immunotherapy : CII|March 7, 2009
The immunologic aspects of poxvirus oncolytic therapyAndrea Worschech, D Haddad, D F Stroncek, et al.
BMC Cancer|February 16, 2011
Viral-mediated oncolysis is the most critical factor in the late-phase of the tumor regression process upon vaccinia virus infectionStephanie Weibel, Viktoria Raab, Yong A Yu, et al.
Expert Opinion on Biological Therapy|February 26, 2008
Spontaneous and treatment-induced cancer rejection in humansEna Wang, Silvia Selleri, Marianna Sabatino, et al.
Journal of Translational Medicine|October 8, 2011
Distinct signatures of the immune responses in low risk versus high risk neuroblastomaMadhu Gowda, Kamar Godder, Maciej Kmieciak, et al.
Plos One|February 27, 2013
Molecular signatures associated with HCV-induced hepatocellular carcinoma and liver metastasisValeria De Giorgi, Luigi Buonaguro, Andrea Worschech, et al.
Cancer Research|April 3, 2008
Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumorsAndrea Worschech, Maciej Kmieciak, Keith L Knutson, et al.
Idrugs : the Investigational Drugs Journal|May 12, 2009
Antitumor vaccines, immunotherapy and the immunological constant of rejectionEna Wang, Alessandro Monaco, Vladia Monsurró, et al.
Breast Cancer Research and Treatment|May 19, 2010
CD4+ T cells inhibit the neu-specific CD8+ T-cell exhaustion during the priming phase of immune responses against breast cancerMaciej Kmieciak, Andrea Worschech, Hooman Nikizad, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Trends in Immunology|May 7, 2008
The immunologic constant of rejectionEna Wang, Andrea Worschech, Francesco M Marincola
Advances in Experimental Medicine and Biology|August 28, 2010
Analysis of vaccine-induced T cells in humans with cancerStefanie L Slezak, Andrea Worschech, Ena Wang, et al.
Cancer Immunology, Immunotherapy : CII|March 7, 2009
The immunologic aspects of poxvirus oncolytic therapyAndrea Worschech, D Haddad, D F Stroncek, et al.
BMC Cancer|February 16, 2011
Viral-mediated oncolysis is the most critical factor in the late-phase of the tumor regression process upon vaccinia virus infectionStephanie Weibel, Viktoria Raab, Yong A Yu, et al.
Expert Opinion on Biological Therapy|February 26, 2008
Spontaneous and treatment-induced cancer rejection in humansEna Wang, Silvia Selleri, Marianna Sabatino, et al.
Journal of Translational Medicine|October 8, 2011
Distinct signatures of the immune responses in low risk versus high risk neuroblastomaMadhu Gowda, Kamar Godder, Maciej Kmieciak, et al.
Plos One|February 27, 2013
Molecular signatures associated with HCV-induced hepatocellular carcinoma and liver metastasisValeria De Giorgi, Luigi Buonaguro, Andrea Worschech, et al.
Cancer Research|April 3, 2008
Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumorsAndrea Worschech, Maciej Kmieciak, Keith L Knutson, et al.
Idrugs : the Investigational Drugs Journal|May 12, 2009
Antitumor vaccines, immunotherapy and the immunological constant of rejectionEna Wang, Alessandro Monaco, Vladia Monsurró, et al.
Breast Cancer Research and Treatment|May 19, 2010
CD4+ T cells inhibit the neu-specific CD8+ T-cell exhaustion during the priming phase of immune responses against breast cancerMaciej Kmieciak, Andrea Worschech, Hooman Nikizad, et al.
Pageof 3